Amir Ebrahim Miroliaee1, Jamshid Salamzadeh1, Shervin Shokouhi2, Zahra Sahraei3. 1. Clinical Pharmacy Department, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 2. Department of Infectious Diseases, Loghman Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 3. Clinical Pharmacy Department, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Electronic address: Z.sahraei@sbmu.ac.ir.
Abstract
PURPOSE: In regard with the effect of immune-stimulants in the treatment of infectious diseases, the effect of vitamin D administration on the outcome of patients with Ventilator-Associated Pneumonia (VAP) with a high rate of mortality, was studied. MATERIAL AND METHOD: In this trial, 46 adult patients suffering from VAP and vitamin D deficiency were enrolled. The first group of patients received single intramuscular injection of vitamin D (300000Unit), while the other group were given the placebo. RESULTS: Administration of vitamin D significantly enhanced its levels (P<0.0001) in the treated patients (12.28±8.26) in comparison with placebo group (1.15±1.50). Serum Interleukin-6 levels were significantly reduced in the treated group compared to placebo (P=0.01). Although C-Reactive protein (CRP) levels showed an improving trend in the vitamin D group, no significant difference between groups (P=0.12) was found. Interestingly, the mortality rate of patients that treated with vitamin D (5/24) was significantly lower (p=0.04) than that of the placebo group (11/22). CONCLUSION: Our results indicate that vitamin D administration can significantly reduce the IL-6 as prognostic marker in VAP patients, and must be considered as adjunct option in the treatment of VAP patients.
RCT Entities:
PURPOSE: In regard with the effect of immune-stimulants in the treatment of infectious diseases, the effect of vitamin D administration on the outcome of patients with Ventilator-Associated Pneumonia (VAP) with a high rate of mortality, was studied. MATERIAL AND METHOD: In this trial, 46 adult patients suffering from VAP and vitamin D deficiency were enrolled. The first group of patients received single intramuscular injection of vitamin D (300000Unit), while the other group were given the placebo. RESULTS: Administration of vitamin D significantly enhanced its levels (P<0.0001) in the treated patients (12.28±8.26) in comparison with placebo group (1.15±1.50). Serum Interleukin-6 levels were significantly reduced in the treated group compared to placebo (P=0.01). Although C-Reactive protein (CRP) levels showed an improving trend in the vitamin D group, no significant difference between groups (P=0.12) was found. Interestingly, the mortality rate of patients that treated with vitamin D (5/24) was significantly lower (p=0.04) than that of the placebo group (11/22). CONCLUSION: Our results indicate that vitamin D administration can significantly reduce the IL-6 as prognostic marker in VAP patients, and must be considered as adjunct option in the treatment of VAP patients.
Authors: E Brizola; G Adami; G I Baroncelli; M F Bedeschi; P Berardi; S Boero; M L Brandi; L Casareto; E Castagnola; P Fraschini; D Gatti; S Giannini; M V Gonfiantini; V Landoni; A Magrelli; G Mantovani; M B Michelis; L A Nasto; L Panzeri; E Pianigiani; A Scopinaro; L Trespidi; A Vianello; G Zampino; L Sangiorgi Journal: Orphanet J Rare Dis Date: 2020-08-31 Impact factor: 4.123
Authors: Daniel M McCartney; Paula M O'Shea; John L Faul; Martin J Healy; Greg Byrne; Tomás P Griffin; James Bernard Walsh; Declan G Byrne; Rose Anne Kenny Journal: Ir J Med Sci Date: 2020-11-21 Impact factor: 2.089